Skip to content

Effect of Naltrexone and Ondansetron in alcohol dependent patients.

Comparing the efficacy of Naltrexone and Ondansetron in patients with alcohol dependence.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/10/037301
Enrollment
80
Registered
2021-10-13
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F102- Alcohol dependence

Interventions

Intervention1: Tab Naltrexone: A known anti-craving drug is given along with the treatment for alcohol dependence. It is given 50 mg via oral route once a day. Control Intervention1: Tablet Ondansetro

Sponsors

Vinayaga Mission Medical College
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients diagnosed under Code 6C40.2: Alcohol dependence under ICD-11 Complete abstinence for 7 days No withdrawal symptoms

Exclusion criteria

Exclusion criteria: Diagnosed under Code 6C40.3: Alcohol Intoxication Diagnosed under Code 6C40.4: Alcohol Withdrawal Diagnosed under Code 6C41: Disorders due to use of Cannabis Diagnosed under Code 6C42: Disorders due to use of synthetic cannabinoids Diagnosed under Code 6C43: Disorders due to use of opioids A current mental or psychiatric impairment or disease that required psychotropic medication or inpatient treatment on a psychiatric ward Current use of any psychotropic medication Evidence of severe neurologic or physical disorders (eg, cerebral, renal, thyroid, or cardiac disease) Homelessness Pregnant women

Design outcomes

Primary

MeasureTime frame
QuestionnaresTimepoint: Week 0,2,4,6,8,10,12

Secondary

MeasureTime frame
NoneTimepoint: -

Countries

India

Contacts

Public ContactDr Rupinder Gill

Vinayaka Mission Medical College and Hospital, Karaikal

rtkannapiran@yahoo.com9360342881

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026